GPR37 Activation Alleviates Bone Cancer Pain via the Inhibition of Osteoclastogenesis and Neuronal Hyperexcitability
Advanced Science · 2025-04 · 12 (14)
DOI: 10.1002/advs.202417367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 18.02.2025. Verfasst von Kaiyuan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Labor…. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Bone Neoplasms, Cancer Pain, Osteogenesis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major Project of Tianjin Public Health Science and Technology Program, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Project.
Abstract (Originalsprache)
Osteolytic bone cancer pain is a primary concern for cancer patients with bone metastasis, and current therapies offer inadequate pain relief. The present study demonstrates that activation of the G protein‐coupled receptor 37 (GPR37) by neuroprotectin D1 (NPD1) or artesunate (ARU) alleviates both acute and persistent pain in multiple mouse models of bone cancer. GPR37 agonists also protect against cancer‐induced bone destruction. Mechanistically, NPD1 or ARU binding to GPR37 in macrophages promotes the release of IL‐10, which further inhibits cancer‐induced osteoclastogenesis. Moreover, direct activation of GPR37 in dorsal root ganglion (DRG) neurons and the spinal dorsal horn reduces action potential firing and the frequency of spontaneous excitatory postsynaptic currents (sEPSCs), thereby suppressing cancer‐induced neuronal hyperexcitability. Importantly, the analgesic and protective effects of NPD1 and ARU are abolished in Gpr37 −/− mice, and β‐arrestin 2 is identified as a key mediator in IL‐10 release and neuronal inhibition. In patients with bone metastases, plasma levels of endogenous NPD1 are negatively correlated with both pain intensity and the bone resorption marker CTX‐I. Collectively, these findings highlight GPR37 activation as a potential therapeutic strategy for alleviating bone cancer pain through direct and synergistic inhibition of osteoclastogenesis and neuronal hyperexcitability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine…
- Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
- Shenzhen University Medical School, Shenzhen, Guangdong, 518060, China.
- Department of Pain Medicine and Shenzhen Municipal Key Laboratory for Pain Medicine, The 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518052, China.
ORCID-Profile: Kaiyuan Wang
Förderung
- National Natural Science Foundation of China
- Major Project of Tianjin Public Health Science and Technology Program
- State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine Project
- Tianjin 'Project + Team' Key Cultivation Program
- Tianjin Key Medical Discipline (Specialty) Construction Project
Zitieren
APA
Wang, K., Zhang, Y., Shu, R., Yuan, L., Tu, H., Wang, S., Ni, B., Zhang, Y. F., Jiang, C., Luo, Y., & Yin, Y. (2025). GPR37 Activation Alleviates Bone Cancer Pain via the Inhibition of Osteoclastogenesis and Neuronal Hyperexcitability. Advanced Science, 12(14). https://doi.org/10.1002/advs.202417367
Vancouver
Wang K, Zhang Y, Shu R, Yuan L, Tu H, Wang S, et al. GPR37 Activation Alleviates Bone Cancer Pain via the Inhibition of Osteoclastogenesis and Neuronal Hyperexcitability. Advanced Science. 2025;12(14). doi:10.1002/advs.202417367
BibTeX
@article{Wang2025,
author = {Wang, Kaiyuan and Zhang, Yongfang and Shu, Ruichen and Yuan, Limei and Tu, Huifang and Wang, Shengran and Ni, Bo and Zhang, Yi-Fan and Jiang, Changyu and Luo, Yuhui and Yin, Yiqing},
title = {GPR37 Activation Alleviates Bone Cancer Pain via the Inhibition of Osteoclastogenesis and Neuronal Hyperexcitability},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {14},
doi = {10.1002/advs.202417367}
}
EUVIMED